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Patrick T. O’Gara, MD, MACC, ACC Immediate Past-PresidentT he American College of Cardiology’s (ACC’s)mission to transform cardiovascular (CV)care and improve heart health requires a
willingness to examine current practices across all
aspects of the care continuum, as well as the critical
contributions of research and innovation to the cycle
of quality improvement. Concerns have been raised
that the U.S. research enterprise has become stagnant
and that we have begun to lose our global leadership
role in innovation and health care delivery. New tech-
nologies, devices, biological agents, and medications
are often ﬁrst available outside of the United States.
There is growing recognition that we must advocate
to ensure that CV patients in the United States can
gain more timely access to medical, interventional,
and surgical innovations shown to be effective and
safe. In parallel, we need to advance comparative
effectiveness and health services research.
To date, efforts by the College to engage federal
policymakers in the area of medical research and
innovation policy have been sporadic and focused on
particular areas of interest. Given the current climate
for research funding, and amid real concerns that the
United States is lagging in its efforts, it is imperative
that the College bring a strategic and organized
approach to these issues. To effect change, it is impor-
tant to identify key areas where the ACC can have the
greatest impact, taking advantage of its member base,
scientiﬁc expertise, and focus on quality improvement.
At the request of the Advocacy Steering Commit-
tee, we undertook an effort to identify strategic areas
of interest to the College, its members, and patients.
Based on interviews with experts from a range of
professional backgrounds, we identiﬁed 3 majorobjectives that will further the College’s mission,
along with the dual goals of promoting support for CV
research and ensuring that U.S. patients have timely
access to cutting-edge, high-quality, safe, and efﬁ-
cient CV care. These objectives include increasing the
availability of funding for research, removing barriers
to clinical research, and developing a learning health
system.
OBJECTIVE 1: INCREASE THE AVAILABILITY
OF FUNDING FOR RESEARCH
Funding sources are stressed. The National Institutes
of Health budget has been stagnant for the past
decade, and foundation and industry support is
limited. The 2015 pay line for grants from the National
Heart, Lung, and Blood Institute is 13% and has hov-
ered between 10% and 13% for the last 5 years (1).
Accordingly, a signiﬁcant amount of important, high-
quality research has not been funded from traditional
sources. Between 1980 and 2013, the average age of
investigators receiving their ﬁrst Research Project
Grant (R01) increased by 6 to 8 years. For PhD in-
vestigators, the average age increased from 36 to
42 years, whereas for MDs, the average age increased
from 38 to 45 years. Individuals with MD-PhDs, on
average, now wait until they are 44, rather than
36 years of age, to achieve their ﬁrst RO1 grant (2).
Increased funding for basic, translational, clinical,
population, and health services research is critical to
reinvigorate the enterprise, improve our ability to
address critical questions, and promote investigation
as a career opportunity for young investigators, all
with the goal of advancing the understanding of CV
disease and developing science-based strategies for
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native funding sources must be identiﬁed and vigor-
ously pursued while the ACC continues its advocacy
efforts to increase federal support.
OBJECTIVE 2: REMOVE BARRIERS
TO RESEARCH
CV trials have become prohibitively expensive because
of their size and scope, as well as numerous regula-
tory inefﬁciencies that often do not advance patient
safety or applicability. There have been increasing
calls for the design and execution of large-scale,
pragmatic clinical trials (3). A recent example of a
trial conducted more efﬁciently than the traditional
randomized controlled trial is the HEAT-PPCI
(Unfractionated Heparin Versus Bivalirudin in Pri-
mary Percutaneous Coronary Intervention) trial, a U.K.
study with a unique design incorporating delayed,
informed consent of research subjects (4). It is not clear
that this trial could have been conducted in the United
States given the issues surrounding informed consent
and the differences across institutional review boards
in the consistent application of policies and regula-
tions. The TASTE (Thrombus Aspiration during ST-
Segment Elevation Myocardial Infarction) trial, a
multicenter, prospective, randomized trial of aspira-
tion thrombectomy at the time of primary PCI con-
ducted in Sweden, used the national comprehensive
SCAAR (Swedish Coronary Angiography and Angio-
plasty Registry) as an online platform for randomiza-
tion, case-record forms, and follow-up data (5). It was
conducted more quickly and at a fraction of the cost of
comparable trials of its type and was highly touted as
an example of the next-generation clinical trial for the
United States (6). A National Cardiovascular Data
Registry (NCDR) registry-based trial, SAFE-PCI (Study
of Access Site for Enhancement of PCI for Women)
Trial, was conducted to assess the effect of radial ar-
tery access on outcomes of women undergoing PCI (7).
It was terminated early because of a lower than ex-
pected event rate, but nevertheless, it highlighted the
potential of the ACC’s patient registries to function as a
platform for randomized trials.
Clinical trials of the future must be more efﬁcient
and less costly, but also address a broad array of
critical questions in populations more representative
of those with or at risk of the condition under study.
To address these concerns, the “pragmatic clinical
trial” must consider streamlining patient enrollment;
incorporating data from a variety of sources,
including clinical registries and electronic health
records, wearable technologies, and “–omics” writ
large; engaging affected patients and their caregivers;and ensuring adequate representation of special
populations, including women, racial and ethnic mi-
norities, the elderly, and the young. There are addi-
tional considerations for smaller populations affected
by less common diseases. This effort will require ex-
amination of current practices, methodologies, and
requirements, such as those in the Common Rule and
the Food and Drug Administration’s research regula-
tions that conﬂict, complicating the use of registry
data for product label expansion (8). The ultimate
goal is to incorporate clinical research into practice in
ways that are seamless for both the patient and the
clinical provider.
The government plays a substantial role in medical
research and innovation; it funds research and de-
ﬁnes the processes by which patients gain access to
new therapies. Although it is the role of government
to ensure that patients receive timely access to safe
and effective therapies, it is also incumbent upon
government to implement policies and processes that
are free of unnecessary burdens and complexities,
obstacles that ultimately only serve to delay access to
lifesaving technologies and increase the cost of those
therapies. Some of these concerns could be reﬂected
in the delay of access to transcatheter aortic valve
replacement (TAVR) in the United States. The United
States was the 44th country to approve TAVR for
commercial use (9). Last, it is essential that these
processes to streamline clinical and health systems
research provide opportunities for patients, care-
givers, and the public to participate.
OBJECTIVE 3: DEVELOP AND IMPLEMENT
A LEARNING HEALTH SYSTEM
As data become easier to collect and are increasingly
mobile, they can be used for a wider variety of pur-
poses. To date, health systems research has been
sorely neglected. Research into improving quality
and reducing costs is essential. It is equally important
to ensure that the results of any comparative effec-
tiveness research project are provided to clinicians
and health systems to improve care delivery and
patient outcomes. We need more initiatives like
Door-to-Balloon (D2B), which was developed based
on research indicating that timeliness of reperfusion
therapy for patients with myocardial infarctions was
key to improving outcomes (10). Additionally, we
need greater ability to use data gathered on patient
care to further improve and reﬁne that care. It is
encouraging that the Food and Drug Administration
decided to expand the label indication for the
Edwards Sapien transcatheter aortic valve (Edwards
Lifesciences, Irvine, California) using prospectively
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ACC TVT (Transcatheter Valve Therapy) Registry data
(11). The use of previously collected data for multiple
purposes is encouraged. Importantly, patients must
be fully engaged at each step and must be provided
transparent information regarding the many ways
their participation in research, even as an entrant in a
registry, can help close our knowledge gaps.
CONCLUSIONS
Much work lies ahead and the actions of many others
will be needed to achieve our aims. The identiﬁcationof these 3 objectives is just the ﬁrst step in the pro-
cess. Among the next steps are the further reﬁnement
of the College’s priorities, the development of policy
positions, and the identiﬁcation of partners with
similar agendas and goals. We look forward to
achieving the ultimate goal of better outcomes for CV
patients.
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